According to the observations of the clinical cases, CT1812 can reverse the expression of AD-related proteins dysregulation and reduce the concentrations of phosphorylated tau fragments, which is associated with another mainstream hypothesis of AD [81]. The gene discussed is MAPT; the disease is Alzheimer disease.